Charles River Laboratories InternationalNYSE: CRL

Charles River (CRL) has a strong track record of surprising with its earnings and currently has the right mix of factors that suggest it may exceed expectations in its upcoming quarterly report.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories has announced the date for their third-quarter 2024 earnings release and conference call.

Charles River and Lundbeck have made a deal to use Logica in order to help discover new neurological medications.

STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical firm using its unique HyNap™ technology to create better cancer treatments, has reported important advancements after a successful meeting with the U.S. Food and Drug Administration (FDA). The company intends to resubmit its New Drug Application (NDA) for Dasynoc in the fourth quarter of 2024, taking into account the feedback from the Complete Response Letter (CRL) received from the FDA in July 2024. If the FDA establishes a timeline.

Charles River is working together with CEBINA on the DanubeNeuro program to promote new ideas in the field of neurodegeneration.

New biological information has been published from the IRO® Cell Therapy Manufacturing Platform. This data provides insights into the platform's capabilities. It highlights advancements in cell therapy production.

Charles River has formed a new partnership with Insightec to enhance the development of therapies that use focused ultrasound in the field of neuroscience.

Charles River (CRL) shared its earnings report 30 days ago. What can we expect for the stock moving forward?

Charles River has reported another set of disappointing figures, suggesting that the company may face a challenging period ahead. The management is reducing capital expenditures and prioritizing share buybacks, which indicates a lack of good investment opportunities for growth. Based on current conditions, I believe the company's true value is between $215 and $223 per share, which means it would be wise to hold onto the stock.